In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Hologic Buys Interlace Medical, Acquires Missing Link In Gynecology Surgery

Executive Summary

Gynecologists generally have the opportunity to perform in-office procedures for three indications: abnormal uterine bleeding, permanent contraception and uterine fibroids. Hologic had supplied its 460 medical device reps in the US - the largest force in women's health - with the tools to perform two of these procedures, but couldn't offer the third piece of the puzzle, an in-office treatment for fibroids, a gap which, until now, hasn't been filled by any product on the market. Hologic is filling in the missing piece with the acquisition of privately held Interlace Medical, a start-up developing MyoSure, a minimally invasive resection device for submucosal fibroids.

You may also be interested in...



Building Interventional Gynecology

Once a sluggish category for clinical innovation, gynecology is drawing new venture-backed companies eager to build upon the lead created by first-generation companies operating in minimally-invasive endometrial ablation and female sterilization. First generation companies had the difficult task of creating paths to early adopters of minimally invasive procedures. These now exist, and the clinical specialty appears to be also evolving in ways that encourage the growth of in-office procedures.

American Injectables $10m Investment Bolsters Domestic Production

American Injectables plans to build up its US-based manufacturing after securing a commitment for $10m of ‘Series A’ financing from New Rhein Healthcare Investors, which it will use to scale up production and launch several generic parenteral products.

EMA Consults On Using Registry Studies As RWE Source

A draft EU guideline explains how disease registries can be used to supplement evidence in the pre-authorization phase and provide infrastructure for post-authorization evidence generation.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

MT142313

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel